← 返回

抗 PD-L1 抗体通过抗体依赖性细胞介导的细胞毒性介导肝细胞癌中 PD-L1(high)CD11b(+) 细胞清除,增强冷冻消融的疗效

英文原题:Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1(high)CD11b(+) cells elimination in hepatocellular carcinoma.

查看英文原题

Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1(high)CD11b(+) cells elimination in hepatocellular carcinoma.

PubMed 2022/08/18(内容时间) Acta Pharm Sin B Q1 · IF 14.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

冷冻消融(CRA)和微波消融(MWA)是肝细胞癌(HCC)的两种主要局部治疗方法,但哪一种根治效果更好、哪一种更适合与免疫疗法联用,仍存在争议。

本研究发现,在 HCC 中,与 MWA 相比,CRA 诱导更高的肿瘤 PD-L1 表达和更多 T 细胞浸润,但 PD-L1 高表达 CD11b⁺ 髓系细胞浸润较少。

此外,在小鼠模型中,CRA 联合抗 PD-L1 治疗的效果优于 MWA 联合治疗。机制上,CRA 治疗后抗 PD-L1 抗体通过增强 cDC1 细胞分泌 CXCL9,促进 CD8⁺ T 细胞浸润。另一方面,CRA 治疗后抗 PD-L1 抗体通过抗体依赖性细胞介导细胞毒作用(ADCC)促进 NK 细胞浸润,清除 PD-L1 高表达 CD11b⁺ 髓系细胞。这两方面均可缓解 CRA 治疗后的免疫抑制微环境。

值得注意的是,与突变型 PD-L1 抗体 atezolizumab(Tecentriq)相比,野生型 PD-L1 抗体 avelumab(Bavencio)更能诱导 ADCC,以靶向 PD-L1 高表达 CD11b⁺ 髓系细胞。

综上,本研究揭示了 CRA 联合抗 PD-L1 抗体通过增强 CTL/NK 细胞免疫应答,较 MWA 联合治疗具有更优疗效,为临床 HCC 治疗采用 CRA 联合 PD-L1 阻断提供了有力依据。

展开英文摘要原文

Cryoablation (CRA) and microwave ablation (MWA) are two main local treatments for hepatocellular carcinoma (HCC).

However, which one is more curative and suitable for combining with immunotherapy is still controversial.

Herein, CRA induced higher tumoral PD-L1 expression and more T cells infiltration, but less PD-L1 high CD11b + myeloid cells infiltration than MWA in HCC.

Furthermore, CRA had better curative effect than MWA for anti-PD-L1 combination therapy in mouse models.

Mechanistically, anti-PD-L1 antibody facilitated infiltration of CD8 + T cells by enhancing the secretion of CXCL9 from cDC1 cells after CRA therapy. On the other hand, anti-PD-L1 antibody promoted the infiltration of NK cells to eliminate PD-L1 high CD11b + myeloid cells by antibody-dependent cell-mediated cytotoxicity (ADCC) effect after CRA therapy. Both aspects relieved the immunosuppressive microenvironment after CRA therapy.

Notably, the wild-type PD-L1 Avelumab (Bavencio), compared to the mutant PD-L1 atezolizumab (Tecentriq), was better at inducing the ADCC effect to target PD-L1 high CD11b + myeloid cells. Collectively, our study uncovered the novel insights that CRA showed superior curative effect than MWA in combining with anti-PD-L1 antibody by strengthening CTL/NK cell immune responses, which provided a strong rationale for combining CRA and PD-L1 blockade in the clinical treatment for HCC.

论文信息

作者
Tan J、Liu T、Fan W、Wei J、Zhu B、Liu Y、Liu L、Zhang X
单位
Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.China
期刊
Acta pharmaceutica Sinica. B2023 Feb
原文标识
PubMed 36873191 · DOI 10.1016/j.apsb.2022.08.006